Gene Therapy for Duchenne Muscular Dystrophy
CRISPR-Cas9 Mediated Gene Editing in DMD Patient-Derived iPSC
Keywords:
Duchenne muscular dystrophy, CRISPR-Cas9, induced pluripotent stem cells, dystrophin, knock-in, knock-out, exon reframing, exon skippingAbstract
Duchenne Muscular Dystrophy (DMD) is a severe muscle degener- ation disease caused by gene mutations in the dystrophin gene. The CRISPR-Cas9 system is an emerging potential gene editing tool that utilizes the Cas9 nuclease and DNA double strand breaks (DSB) to make site- specific gene corrections. Induced human pluripotent stem cells (iPSC) are derived from the human body and reprogrammed to become potential stem cells that can differentiate into various human cell lineages. Using CRISPR-Cas9 in iPSCs to correct certain exon mutations in the dystrophin gene provides great advantages in both efficacy and low immunogenicity. This article reviews four main CRISPR-mediated exon correction methods that correct various mutations occurring across the dystrophin gene. In addition, this review discusses current developments and studies utilizing CRISPR-Cas9 to perform gene editing in iPSC derived from DMD patients and evaluates the feasibility of such an integrated gene therapy. To the end, this review compares the advantages and limitations of this gene therapy to other traditional methods and provides future prospective regarding further implementation.
References or Bibliography
Ifuku M Iwabuchi KA Tanaka M Lung MSY Hotta A. Restora- tion of dystrophin protein expression by exon skipping utilizing crispr-cas9 in myoblasts derived from dmd patient ips cells. Meth- ods Mol Biol, 2018.
Doss MX Sachinidis A. Current challenges of ipsc-based disease modeling and therapeutic implications. Cells, 2019.
Bassett AR. Editing the genome of hipsc with crispr/cas9: dis- ease models. Mamm Genome, 2017.
Reddy E Gersbach CA. Na. Published online, 2015.
Chen C Ma H Zhang F et al. Screening of duchenne muscu- lar dystrophy (dmd) mutations and investigating its mutational mechanism in chinese patients. PLoS One, 2014.
Li HL Fujimoto N Sasakawa N et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by talen and crispr-cas9. Stem Cell Re- ports, 2015.
Nelson CE Hakim CH Ousterout DG et al. In vivo editing im- proves muscle function in mouse of dmd. Science, 2016.
Tabebordbar M Zhu K Cheng JKW et al. Duchenne. Science, 2016.
Xu L Park KH Zhao L et al. Crispr-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther, 2016.
Lattanzi A Moiani A Izmiryan A et al. Correction of the exon 2 duplication in dmd myoblasts by a single crispr/cas9 system. Mol Ther - Nucleic Acids, 2017.
Koo T Lu-Nguyen NB Malerba A et al. Functional rescue of dys- trophin deficiency in mice caused by frameshift mutations using campylobacter jejuni cas9. Mol Ther, 2018.
Min YL Li H Rodriguez-Caycedo C et al. Crispr-cas9 corrects duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci Adv, 2019.
et al. C. Crispr correction of duchenne muscular dystrophy. Phys- iol Behav, 2016.
Newman M Ausubel FM. Introduction to gene editing and ma- nipulation using crispr/cas9 technology. Curr Protoc Mol Biol, 2016.
Zhao M Shoji E Sakurai H. In vitro evaluation of exon skipping in disease-specific ipsc-derived myocytes. Methods Mol Biol, 2018.
Liu C Zhang L Liu H Cheng K. Delivery strategies for crispr- cas9 gene-editing systems. HHS Public Access J Control Release, 2017.
Guiraud S Chen H Burns DT Davies KE. Advances in genetic therapeutic strategies for duchenne muscular dystrophy. Exp Physiol, 2015.
Das C Hansen KC and Tyler JK LMS. Engineering the delivery system for crispr-based genome editing. Physiol Behav, 2017.
et al Min YL Chemello F Li H. Correction of three prominent mutations in mouse and human models of duchenne muscular dystrophy by single-cut genome editing. Mol Ther, 2020.
Hagan M Ashraf M Kim I Weintraub NL. Correction. NA, 2019.
Hockemeyer D Jaenisch R. Induced pluripotent stem cells meet genome editing reprogramming: quot; the yamanaka experiment quot. Cell Stem Cell, 2017.
Ortiz Vitali JL Darabi R. Pscs as a platform for disease mod- eling, drug screening, and personalized therapy in muscular dys- trophies. Cells, 2019.
Aslesh T Maruyama R Yokota T. Skipping multiple exons to treat dmd-promises and challenges. Biomedicines, 2018.
Lim KRQ Yoon C Yokota T. Applications of crispr/cas9 for the treatment of duchenne muscular dystrophy. J Pers Med, 2018.
Nakamura A Aoki Y Tsoumpra M Yokota T. Exon skipping and inclusion therapies. NA, 2018.
Rodrigues M Yokota T. An overview of recent advances and clin- ical applications dystrophy and various genetic diseases. Methods Mol Biol, 2018.
Xia G Terada N Ashizawa T. Human ipsc models to study orphan diseases: Muscular dystrophies. Curr Stem Cell Reports, 2018.
Justyna W. Creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of a crispr/ cas9 gene editing therapy. Physiol Behav, 2017.
Li Y Li L Chen ZN Gao G Yao R Sun W. Engineering-derived approaches for ipsc preparation, expansion, differentiation and applications. Biofabrication, 2017.
Cai A Kong X. Development of crispr-mediated systems in the study of duchenne muscular dystrophy. Hum Gene Ther Meth- ods, 2019.
Shimizu-Motohashi Y Komaki H Motohashi N Takeda S Yokota T Aoki Y. Restoring dystrophin expression in duchenne muscular dystrophy: Current status of therapeutic approaches. J Pers Med, 2019.
Wang JZ Wu P Shi ZM Xu YL Liu ZJ. The aav-mediated and rna-guided crispr/cas9 system for gene therapy of dmd and bmd. Brain Dev. 2, 2017.
Downloads
Posted
License
Copyright (c) 2021 Marisa Wen
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright holder for this article has granted JSR.org a license to display the article in perpetuity.
